In the recently reported SAL-Soraml trial, sorafenib demonstrated safety and improved event free survival compared to placebo when used as an adjunct to standard induction chemotherapy in 267 younger (age <60) patients with newly diagnosed AML, only 17% of whom were FLT3-ITD mutated (3-year event-free survival 40% versus 22%, p = 0.013) [109]. The gene discussed is FLT3; the disease is acute myeloid leukemia.